156
Views
12
CrossRef citations to date
0
Altmetric
Original Research

Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination

, , , , &
Pages 499-504 | Published online: 17 Feb 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Sourabh Sharma, Sameer Trikha, Shamira A Perera & Tin Aung. (2015) Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clinical Ophthalmology 9, pages 2201-2207.
Read now
Gábor Holló, Fotis Topouzis & Robert D Fechtner. (2014) Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opinion on Pharmacotherapy 15:12, pages 1737-1747.
Read now
Emilio Rintaro Suzuki$suffix/text()$suffix/text() & Cibele Lima Belico Suzuki. (2010) Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations. Clinical Ophthalmology 4, pages 1165-1171.
Read now

Articles from other publishers (9)

Massomehsadat Masoumpour & حمیده مهدوی‌آزاد. (2019) Compliance with Glaucoma Therapy with Eye Drops and its Determinants in Glaucoma Pa-tients Presenting to Clinics Affiliated to Shiraz University of Medical Sciences. Iranian South Medical Journal 22:2, pages 119-129.
Crossref
Howard S. Barnebey & Alan L. Robin. (2017) Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. American Journal of Ophthalmology 176, pages 61-69.
Crossref
Manon Belhassen, Laurent Laforest, Idlir Licaj & Éric Van Ganse. (2016) Étude observationnelle sur l’adhésion précoce aux traitements hypotonisants anti-glaucomateux. Therapies 71:5, pages 491-499.
Crossref
Satish S. Modi, Robert P. Lehmann, Thomas R. Walters, Raymond Fong, William C. Christie, Lawrence Roel, David Nethery, Dana Sager, Alexis Tsorbatzoglou, Bo Philipson, Carlo E. Traverso & Harvey Reiser. (2014) Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: Phase 3 study. Journal of Cataract and Refractive Surgery 40:2, pages 203-211.
Crossref
Yan-Qing Wang, Xin Wang & Ping Liu. (2013) Meta analysis about the efficacy and safety of anti-ocular hypertension eye drops without benzalkonium chloride. Asian Pacific Journal of Tropical Medicine 6:12, pages 1004-1008.
Crossref
Simon E. Skalicky & Ivan Goldberg. (2013) Adherence and Persistence. Asia-Pacific Journal of Ophthalmology 2:6, pages 356-361.
Crossref
Laura E. Dreer, Christopher Girkin & Steven L. Mansberger. (2012) Determinants of Medication Adherence to Topical Glaucoma Therapy. Journal of Glaucoma 21:4, pages 234-240.
Crossref
Gemma C.M. Rossi, Gian Maria Pasinetti, Luigia Scudeller, Rosella Radaelli & Paolo Emilio Bianchi. (2010) Do Adherence Rates and Glaucomatous Visual Field Progression Correlate?. European Journal of Ophthalmology 21:4, pages 410-414.
Crossref
Manuel Marcel Hermann, Dimitris Papaconstantinou, Philipp Sebastian Muether, Gerasimos Georgopoulos & Michael Diestelhorst. (2011) Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring. Acta Ophthalmologica 89:4, pages e300-e305.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.